Search clinical trials for: BRAF V600 wildtype

Total 745 results

Ohio State University Comprehensive Cancer Center
Novartis Pharmaceuticals; National Comprehensive Cancer Network

Completed

Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal Cancer

United States
Fondazione Melanoma Onlus

Withdrawn

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Melanoma

Italy
Celltrion

Completed

Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects

Healthy Subject

Korea, Republic of
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Active, not recruiting

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (SECOMBIT)

Metastatic Melanoma

Italy, Germany, Spain, Greece, Austria, France, Poland, Sweden, Switzerland, United Kingdom
Intellia Therapeutics

Active, not recruiting

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Wild-Type Transthyretin Cardiac Amyloidosis

France, United Kingdom, New Zealand, Sweden
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Advanced BRAF Mutant Cancers

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma (Neo Trio)

Melanoma

Australia
Fred Hutchinson Cancer Center
Pfizer

Completed

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Acute Myeloid Leukemia

United States
Assistance Publique - Hôpitaux de Paris

Completed

Cobimetinib for BRAF-wild-type or Mutated Histiocytoses (COBRAH)

Disease or R Group Histiocytoses

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Cancer

France, Spain, Netherlands, Canada, Austria, United States, Germany, Italy, Japan, Norway, Korea, Republic of, Denmark, Sweden, Belgium
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

CRC

China
Federation Francophone de Cancerologie Digestive
Amgen

Active, not recruiting

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (OPTIPRIME)

Metastatic Colorectal Cancer

France, Martinique
British Columbia Cancer Agency

Completed

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer (TAPER)

Endometrial Cancer

Canada
Washington University School of Medicine

Terminated

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

Follicular Lymphoma

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

BRAF Positive Metastatic Melanoma

United States
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Langerhans Cell Histiocytosis | Erdheim-Chester Disease | LCH | ECD

China
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation

Metastatic Colorectal Cancer | mCRC

China
Sun Yat-sen University

Active, not recruiting

Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer (C-CLASSIC)

Colorectal Cancer

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Northwestern University; Northwell Health; Dana-Farber... and other collaborators

Active, not recruiting

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Bahria University

Completed

To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea

Irritable Bowel Syndrome With Diarrhea

Pakistan
Intergroupe Francophone de Cancerologie Thoracique

Completed

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Carcinoma, Non-Small-Cell Lung | KRAS Gene Mutation | ALK Gene Mutation | BRAF Gene Mutation

France
Grupo Español Multidisciplinar de Melanoma
Pierre Fabre Medicament; MFAR

Active, not recruiting

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL)

Metastatic Melanoma | Brain Metastases

Spain
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Glioblastoma

United States
Philogen S.p.A.

Completed

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse (GLIOMOON)

Glioma of Brain

Switzerland
Revolution Medicines, Inc.
Sanofi

Completed

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Solid Tumor

United States, Korea, Republic of
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Locally Advanced Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Active, not recruiting

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Thyroid Carcinoma

United States
Washington University School of Medicine

Completed

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Astrocytoma, Grade III | Astrocytoma, Grade IV | Grade IV Astrocytoma | Grade III Astrocytoma

United States
Pfizer

Terminated

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)

Brain Metastases

United States, Belgium, Australia, Argentina, Italy
Rennes University Hospital
QIAGEN Gaithersburg, Inc

Completed

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project (KitMel)

Melanoma

France
Wake Forest University Health Sciences
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs. (ERA)

Heart Disease

United States
Asana BioSciences

Terminated

Study of ASN003 in Subjects With Advanced Solid Tumors

Melanoma | Neoplasms | Colorectal Neoplasm | Carcinoma, Non-small Cell Lung

United States
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Melanoma

United States
Emory University
National Cancer Institute (NCI); GlaxoSmithKline; National Institutes of Health...

Active, not recruiting

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect)

Microsatellite Stable | Stage IV Colorectal Cancer AJCC v8 | RAS Wild Type | MSI-H Colorectal Cancer | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma

United States
Jinsong Wu

Completed

Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection

Glioma, Malignant

China
Novartis Pharmaceuticals

Completed

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Metastatic Melanoma

United States
Revolution Medicines, Inc.
Sanofi; Amgen

Active, not recruiting

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Spain, United Kingdom, Italy, Australia, France, Germany
Royal Cornwall Hospitals Trust
Biocartis

Completed

KEBI-Cyto Study - Use of the Biocartis Idylla

Pancreatic Adenocarcinoma | Lung Cancer

United Kingdom
Oncology Institute of Southern Switzerland
University of Kiel; Ente Ospedaliero Cantonale, Bellinzona

Completed

Prevalence of Wild Type ATTR

Wild-type Transthyretin Amyloidosis

Switzerland
Grupo Espanol de Investigacion en Sarcomas
Bayer

Completed

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)

Gastrointestinal Stromal Tumors

Spain, France, Italy
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Calithera Biosciences, Inc

Active, not recruiting

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | RAS Wild Type Colorectal Cancer | Refractory Colorectal Cancer

United States
Celularity Incorporated

Withdrawn

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02)

Glioblastoma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Astrocytoma, Grade IV

United States
Sun Yat-sen University

Completed

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

China
Yuhong Li

Completed

Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC

Metastatic Colorectal Cancer

China
Karen-Lise Garm Spindler

Completed

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - (OPTIPAL-II)

Colorectal Cancer Metastatic | KRAS Gene Mutation | Circulating Tumor DNA | BRAF Gene Mutation | NRAS Gene Mutation | Epidermal Growth Factor Receptor Inhibitor

Denmark
Pierre Fabre Medicament
Clinact

Completed

A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) (CAPSTAN CRC)

Metastatic Colorectal Cancer | BRAF V600E Mutation Positive

France, United Kingdom, Spain, Belgium, Germany, Italy, Austria
H. Lee Moffitt Cancer Center and Research Institute
Exelixis

Completed

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma

United States
University of California, San Francisco
Bristol-Myers Squibb; Pfizer

Terminated

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditions

United States
Gruppo Oncologico del Nord-Ovest

Completed

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (TRIPLETE)

Metastatic Colorectal Cancer

Italy

Search clinical trials for: BRAF V600 wildtype

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations